Casdin Partners Master Fund, L.P. bought LAB
March 18, 2024 · Form 4 insider transaction
Casdin Partners Master Fund, L.P. bought 13,939,637 shares of Standard BioTools Inc. at $2.75 per share, a transaction worth $38.33M. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
13,939,637
Price
$2.75
Total value
$38.33M
Role—
CompanyStandard BioTools Inc. (LAB)
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateMarch 18, 2024
Filing dateMarch 20, 2024
Shares owned after13,939,637
OwnershipIndirect
10b5-1 planNo
AmendedNo
Footnotes
The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.